Adamax: The Complete Guide
A next-generation Semax derivative built for longer duration — and one of the least-documented peptides in the nootropic space. Here's what's actually known, and what isn't.
This guide summarizes what published information exists on Adamax. It is educational only and not a substitute for advice from a qualified healthcare professional. Sources are listed at the end.
What Adamax Is
Adamax is a synthetic modification of Semax, the Russian nootropic peptide with three decades of clinical history. It belongs to the family of ACTH(4–10)-derived cognitive peptides, and it was created to solve a specific problem with its parent compound: Semax clears from the body extremely fast.
The approach is a familiar one in drug design — take a molecule that works and chemically armour it so it lasts longer and reaches the brain more readily. That's the entire premise of Adamax. Whether it succeeds is a separate question, and one we'll address honestly below.
The Chemistry Behind It
Adamax makes two modifications to the Semax backbone:
N-terminal Acetylation
An acetyl group added to one end blocks aminopeptidases — the enzymes that chew peptides apart — slowing degradation and extending how long the molecule survives.
C-terminal Adamantane
An adamantane "cage" molecule attached to the other end. Adamantane is highly fat-soluble, which is thought to help the peptide cross the blood–brain barrier and further resist breakdown.
Why adamantane, specifically?
The choice isn't arbitrary. Adamantane is a rigid, cage-shaped carbon structure used in established central nervous system drugs — amantadine (for Parkinson's and influenza) and memantine (for Alzheimer's) both use it, precisely because it improves fat solubility and brain penetration. Borrowing that chemistry for a peptide is a rational piece of design. The important caveat: those approved drugs are small molecules, not peptide conjugates, so how well the safety and behaviour of adamantane transfers to a peptide is genuinely less established.
Clearing Up the Naming Confusion
Adamax is frequently confused with its siblings, and some vendors use the names interchangeably — incorrectly. The Semax family works like this:
| Compound | Modification |
|---|---|
| Semax | The original ACTH(4–10) heptapeptide with a Pro-Gly-Pro stabilising tail |
| N-Acetyl Semax (NA-Semax) | Adds N-terminal acetylation for greater stability |
| NA-Semax-Amidate (NASA) | Adds acetylation plus C-terminal amidation |
| Adamax | Adds acetylation plus a C-terminal adamantane group |
Adamax is not NA-Semax-Amidate
Some suppliers label Adamax as "NA-Semax-Amidate" or treat the two as the same product. They aren't — one carries an amide group at the C-terminus, the other an adamantane cage. If a vendor conflates them, that tells you something about how carefully they characterise what they sell. Always check the certificate of analysis to see what the material actually is; our guide on understanding purity and COAs explains how.
The Evidence Situation (Read This Part)
We'd rather be straight with you than sell you a story. Here is the honest position on Adamax:
Adamax has almost no published research under its own name
Semax has an extensive research record — decades of Russian clinical use, published BDNF and stroke studies, real human data. Adamax does not. Essentially everything claimed about it is extrapolated from Semax plus the theoretical expectation that its modifications improve durability. There is no head-to-head study establishing that Adamax actually outperforms Semax or NA-Semax-Amidate, no published human pharmacokinetic data under its own name, and no long-term safety data for adamantane-conjugated peptides given chronically. The chemistry is rational; the confirmation is missing.
That doesn't mean Adamax doesn't work — it means nobody has demonstrated that it does, specifically, in the way vendors describe. Anyone considering it should understand they're choosing a theoretically-designed compound over a comparatively well-studied parent, and that "newer and stronger" is a marketing claim here rather than an established finding.
How It's Thought to Work
Adamax's presumed mechanism is inherited from Semax, since it shares the same active backbone:
- BDNF and TrkB signalling — Semax rapidly increases BDNF (brain-derived neurotrophic factor) and activates its TrkB receptor, driving neuroplasticity, learning, and memory. In rat hippocampus, a single Semax dose has been shown to raise BDNF protein around 1.4-fold and TrkB phosphorylation around 1.6-fold.
- Melanocortin receptor activity — as an ACTH fragment derivative, it interacts with melanocortin receptors involved in attention and arousal, without the hormonal (cortisol-raising) portion of ACTH.
- Neurotransmitter modulation — Semax influences dopamine turnover, consistent with effects on focus and motivation.
- Neuroprotection — the parent compound has documented neuroprotective effects, which underpin its use in Russian stroke care.
Note the framing throughout: these are Semax's established mechanisms, which Adamax is assumed to share. For the wider picture, see our pillar on nootropic peptides explained.
Reported Effects
What follows comes from user reports within the nootropic community rather than controlled trials, and should be weighted accordingly:
Focus & Clarity
Improved concentration and mental clarity, often described as cleaner and more sustained than Semax.
Verbal Fluency
Easier word-finding and articulation — a commonly and specifically reported effect in this family.
Motivation & Drive
Increased mental energy and willingness to engage with demanding tasks.
Longer Duration
The central selling point — effects reported to last longer per dose than Semax, meaning fewer administrations.
As with all nootropic peptides, expect something subtle. These compounds support cognitive function rather than transforming it, and anyone anticipating a dramatic change will be disappointed.
Dosing — and a Serious Caution
We're not going to publish a confident dosing protocol for Adamax, and it's worth explaining exactly why.
Published dosing guidance varies by more than 100-fold
Search for Adamax dosing and you'll find recommendations ranging from around 50 micrograms per day at the low end to 15 milligrams per day at the high end — a difference of several hundred times. Those figures cannot all be right. Some sources describe it as three to five times more potent than Semax (implying much smaller doses); others quote milligram amounts that would be extraordinary for a peptide in this family. This spread is the clearest possible evidence that reliable dosing data for Adamax does not exist — the numbers circulating online are estimates, extrapolations, and in some cases probably errors. Publishing one as though it were established would be irresponsible, so we won't.
What we can say responsibly: Adamax is used intranasally (and sometimes subcutaneously), it is generally regarded as more potent per microgram than Semax rather than less, and community protocols typically involve cycling with breaks rather than continuous use. Anyone considering it should treat conservative dosing and professional guidance as essential, verify the concentration of their specific product against its certificate of analysis, and understand that they are working without a validated reference point.
Adamax vs Semax
| Semax | Adamax | |
|---|---|---|
| Research base | Extensive — decades of clinical use | Minimal under its own name |
| Regulatory history | Approved medication in Russia | None |
| Duration | Shorter — often multiple daily doses | Designed to last longer per dose |
| Dosing confidence | Well established | Highly inconsistent across sources |
| Best suited to | Anyone wanting the evidence-backed option | Those specifically exploring newer derivatives |
Our honest recommendation
If you're new to this family, start with Semax. It has the clinical history, the published mechanism data, established dosing, and a known safety profile — everything Adamax lacks. Adamax makes more sense as something to explore after you understand how you respond to Semax, if you specifically want longer duration and accept the trade-off of a much thinner evidence base. For the calming counterpart in this family, see Selank and our Selank vs Semax comparison.
Safety & Regulatory Status
What to know
Adamax is not approved by the FDA or any major regulatory agency and is sold as a research compound. No formal safety studies exist for it specifically, and the long-term safety of adamantane-conjugated peptides taken chronically is unknown — the approved adamantane drugs are small molecules, not peptides, so that reassurance doesn't transfer cleanly. Reported side effects in the community mirror Semax's (mild nasal irritation from intranasal use, occasional headache, overstimulation at higher doses), but there is no systematic adverse-event data. Because it acts on brain chemistry, anyone taking psychiatric or neurological medication, or with a related condition, should consult a healthcare professional first. Significant cognitive difficulties or low mood deserve proper medical evaluation rather than self-experimentation. See our when to consult a doctor guide.
Common Questions
What is Adamax?
Adamax is a synthetic modification of Semax, the Russian nootropic peptide derived from ACTH(4–10). It adds two changes to the Semax backbone: N-terminal acetylation to resist enzyme breakdown, and a C-terminal adamantane group to improve fat solubility and brain penetration. The design goal is a longer-lasting version of Semax requiring fewer doses. It's sold as a research compound and has minimal published research under its own name.
Is Adamax the same as NA-Semax-Amidate?
No, though some vendors treat them as interchangeable. Both start from N-acetylated Semax, but NA-Semax-Amidate carries a C-terminal amide group while Adamax carries an adamantane cage structure. They're different compounds with different properties. If a supplier labels them as the same thing, that's a useful signal about how carefully they characterise their products — check the certificate of analysis to confirm what you're actually getting.
Is Adamax stronger than Semax?
It's designed to be longer-lasting and is generally described as more potent per microgram, but this hasn't been demonstrated in published head-to-head research. There's no study establishing that Adamax outperforms Semax or NA-Semax-Amidate, and no published human pharmacokinetic data under its own name. The chemistry rationale is sound — the modifications are the kind used in real CNS drugs — but "stronger" is currently a theoretical expectation and marketing claim rather than a proven finding.
How is Adamax dosed?
Honestly, there's no reliable answer — and that's important to know. Published guidance ranges from roughly 50 micrograms to 15 milligrams daily, a difference of several hundred times, which shows that validated dosing data simply doesn't exist. It's used intranasally (sometimes subcutaneously) and generally considered more potent per microgram than Semax, with community protocols involving cycling. Anyone considering it should be conservative, verify their product's concentration against its COA, and seek professional guidance.
Should I use Adamax or Semax?
If you're new to this family, Semax — clearly. It has decades of clinical history, published mechanism data including BDNF and TrkB findings, established dosing, an approval history in Russia, and a known safety profile. Adamax has none of those. It makes more sense as something to explore after you know how you respond to Semax, if you specifically want longer duration and are comfortable accepting a much thinner evidence base in exchange.
Is Adamax safe?
Nobody can answer that with confidence, because no formal safety studies exist for it. Community-reported side effects mirror Semax's — mild nasal irritation, occasional headache, overstimulation at higher doses — but there's no systematic adverse-event data. The long-term safety of adamantane-conjugated peptides taken chronically is unknown; the approved adamantane drugs are small molecules rather than peptides, so their safety record doesn't transfer directly. It's not approved by any major regulator.
Can Adamax be combined with Selank?
Pairing a stimulating cognitive peptide with a calming anxiolytic is a common approach in this family, and Selank is the usual counterpart — the logic being focus plus composure. However, combination data is anecdotal rather than trial-based, and combining a well-characterised peptide with a poorly-characterised one compounds the uncertainty. If you're interested in that pairing, doing it with Semax rather than Adamax gives you at least one component with a solid evidence base.
Questions about Adamax?
We're happy to talk through how it compares to Semax, share the certificate of analysis for our batch, or tell you honestly when we think a better-studied option would serve you better. We answer every message personally, with no pressure and no upsell.
Contact Us on WhatsAppImportant disclaimer: The information in this guide is general educational content only. It is not medical advice, a prescription, or a personalized recommendation. Adamax is not approved by the FDA, Costa Rica's Ministerio de Salud, or any other major regulatory agency for any use; it is sold as a research compound intended for laboratory and scientific study, not as a substitute for prescribed, medically supervised treatment. Adamax has essentially no published research under its own name — the mechanisms described here are those established for its parent compound Semax and are assumed rather than demonstrated for Adamax, and no head-to-head data establishes any advantage over better-studied alternatives. No validated human dosing exists, and published dosing guidance varies by more than a hundredfold; nothing on this page should be treated as a dosing recommendation. Long-term safety data for adamantane-conjugated peptides is not available. Anyone taking psychiatric or neurological medication, or with a related condition, should consult a qualified healthcare professional before considering it. Products sold by Peptides Costa Rica are intended for laboratory and research purposes only.
- Brain Research (Dolotov et al., 2006): Semax, an analog of ACTH(4–10), regulates BDNF and trkB expression in the rat hippocampus (parent compound).
- Zhurnal Vysshei Nervnoi Deiatelnosti (Ashmarin et al., 1997): Nootropic ACTH(4–10) analog Semax — 15 years of design and study (parent compound).
- NCBI/PMC: Semax neuroprotection, dopaminergic modulation, and ischemic stroke research (parent compound).
- NCBI/PMC: Adamantane derivatives in CNS pharmacology — lipophilicity, blood–brain barrier penetration, amantadine and memantine.
- Peptide reference databases (2026): Adamax structural characterisation — N-acetylation and C-terminal adamantane modification; noted absence of independent published research.
- Nature Reviews Drug Discovery: "Therapeutic peptides: current applications and future directions."
